Platinum-based chemotherapy for advanced non-small-cell lung cancer

Anne M. Traynor, Joan H. Schiller

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Summary: Platinum compounds provide the foundation for the treatment of patients with advanced NSCLC. Treatments with such regimens offer patients with an improvement in good performance status, in quality of life and prolonged survival, compared to BSC. Carboplatin very likely offers similar efficacy outcomes compared to cisplatin in this setting, and with less toxicity. Treatment with a platinum-based doublet incorporating a newer, third-generation cytotoxic agent is the recommended therapy for good-performance-status patients with advanced NSCLC, yielding an approximate response rate of 30%, median survival of 8-12 months, 1-year survival of 30%, and 2-year survival of 10%. No single regimen is recommended as superior; selection of the regimen can be flexible, contingent upon the patient's comorbidities, treatment cost, and administration schedule. Adding a third cytotoxic agent is only likely to exacerbate toxicity, without improving efficacy. Treatment should be limited to four cycles in patients with stable disease, and possibly a maximum of six cycles, as tolerated, in responding patients. Age alone should not preclude consideration for treatment with a platinum doublet, although prospective data using platinum agents in studies restricted to elderly patients are lacking. Finally, research continues into the identification of platinum-sensitive patients based upon pharmacoge-nomic parameters, and the development of newer platinum compounds.

Original languageEnglish (US)
Title of host publicationTumors of the Chest: Biology, Diagnosis and Management
PublisherSpringer Berlin Heidelberg
Pages273-288
Number of pages16
ISBN (Print)6293603618, 9783540310396
DOIs
StatePublished - 2006

Fingerprint

Platinum
Non-Small Cell Lung Carcinoma
Drug Therapy
Platinum Compounds
Survival
Cytotoxins
Therapeutics
Carboplatin
Health Care Costs
Cisplatin
Comorbidity
Appointments and Schedules
Quality of Life
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Traynor, A. M., & Schiller, J. H. (2006). Platinum-based chemotherapy for advanced non-small-cell lung cancer. In Tumors of the Chest: Biology, Diagnosis and Management (pp. 273-288). Springer Berlin Heidelberg. https://doi.org/10.1007/3-540-31040-1_22

Platinum-based chemotherapy for advanced non-small-cell lung cancer. / Traynor, Anne M.; Schiller, Joan H.

Tumors of the Chest: Biology, Diagnosis and Management. Springer Berlin Heidelberg, 2006. p. 273-288.

Research output: Chapter in Book/Report/Conference proceedingChapter

Traynor, AM & Schiller, JH 2006, Platinum-based chemotherapy for advanced non-small-cell lung cancer. in Tumors of the Chest: Biology, Diagnosis and Management. Springer Berlin Heidelberg, pp. 273-288. https://doi.org/10.1007/3-540-31040-1_22
Traynor AM, Schiller JH. Platinum-based chemotherapy for advanced non-small-cell lung cancer. In Tumors of the Chest: Biology, Diagnosis and Management. Springer Berlin Heidelberg. 2006. p. 273-288 https://doi.org/10.1007/3-540-31040-1_22
Traynor, Anne M. ; Schiller, Joan H. / Platinum-based chemotherapy for advanced non-small-cell lung cancer. Tumors of the Chest: Biology, Diagnosis and Management. Springer Berlin Heidelberg, 2006. pp. 273-288
@inbook{5e6a9acb01c143b2ae8f97fb5de7b483,
title = "Platinum-based chemotherapy for advanced non-small-cell lung cancer",
abstract = "Summary: Platinum compounds provide the foundation for the treatment of patients with advanced NSCLC. Treatments with such regimens offer patients with an improvement in good performance status, in quality of life and prolonged survival, compared to BSC. Carboplatin very likely offers similar efficacy outcomes compared to cisplatin in this setting, and with less toxicity. Treatment with a platinum-based doublet incorporating a newer, third-generation cytotoxic agent is the recommended therapy for good-performance-status patients with advanced NSCLC, yielding an approximate response rate of 30{\%}, median survival of 8-12 months, 1-year survival of 30{\%}, and 2-year survival of 10{\%}. No single regimen is recommended as superior; selection of the regimen can be flexible, contingent upon the patient's comorbidities, treatment cost, and administration schedule. Adding a third cytotoxic agent is only likely to exacerbate toxicity, without improving efficacy. Treatment should be limited to four cycles in patients with stable disease, and possibly a maximum of six cycles, as tolerated, in responding patients. Age alone should not preclude consideration for treatment with a platinum doublet, although prospective data using platinum agents in studies restricted to elderly patients are lacking. Finally, research continues into the identification of platinum-sensitive patients based upon pharmacoge-nomic parameters, and the development of newer platinum compounds.",
author = "Traynor, {Anne M.} and Schiller, {Joan H.}",
year = "2006",
doi = "10.1007/3-540-31040-1_22",
language = "English (US)",
isbn = "6293603618",
pages = "273--288",
booktitle = "Tumors of the Chest: Biology, Diagnosis and Management",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Platinum-based chemotherapy for advanced non-small-cell lung cancer

AU - Traynor, Anne M.

AU - Schiller, Joan H.

PY - 2006

Y1 - 2006

N2 - Summary: Platinum compounds provide the foundation for the treatment of patients with advanced NSCLC. Treatments with such regimens offer patients with an improvement in good performance status, in quality of life and prolonged survival, compared to BSC. Carboplatin very likely offers similar efficacy outcomes compared to cisplatin in this setting, and with less toxicity. Treatment with a platinum-based doublet incorporating a newer, third-generation cytotoxic agent is the recommended therapy for good-performance-status patients with advanced NSCLC, yielding an approximate response rate of 30%, median survival of 8-12 months, 1-year survival of 30%, and 2-year survival of 10%. No single regimen is recommended as superior; selection of the regimen can be flexible, contingent upon the patient's comorbidities, treatment cost, and administration schedule. Adding a third cytotoxic agent is only likely to exacerbate toxicity, without improving efficacy. Treatment should be limited to four cycles in patients with stable disease, and possibly a maximum of six cycles, as tolerated, in responding patients. Age alone should not preclude consideration for treatment with a platinum doublet, although prospective data using platinum agents in studies restricted to elderly patients are lacking. Finally, research continues into the identification of platinum-sensitive patients based upon pharmacoge-nomic parameters, and the development of newer platinum compounds.

AB - Summary: Platinum compounds provide the foundation for the treatment of patients with advanced NSCLC. Treatments with such regimens offer patients with an improvement in good performance status, in quality of life and prolonged survival, compared to BSC. Carboplatin very likely offers similar efficacy outcomes compared to cisplatin in this setting, and with less toxicity. Treatment with a platinum-based doublet incorporating a newer, third-generation cytotoxic agent is the recommended therapy for good-performance-status patients with advanced NSCLC, yielding an approximate response rate of 30%, median survival of 8-12 months, 1-year survival of 30%, and 2-year survival of 10%. No single regimen is recommended as superior; selection of the regimen can be flexible, contingent upon the patient's comorbidities, treatment cost, and administration schedule. Adding a third cytotoxic agent is only likely to exacerbate toxicity, without improving efficacy. Treatment should be limited to four cycles in patients with stable disease, and possibly a maximum of six cycles, as tolerated, in responding patients. Age alone should not preclude consideration for treatment with a platinum doublet, although prospective data using platinum agents in studies restricted to elderly patients are lacking. Finally, research continues into the identification of platinum-sensitive patients based upon pharmacoge-nomic parameters, and the development of newer platinum compounds.

UR - http://www.scopus.com/inward/record.url?scp=84892789421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892789421&partnerID=8YFLogxK

U2 - 10.1007/3-540-31040-1_22

DO - 10.1007/3-540-31040-1_22

M3 - Chapter

AN - SCOPUS:84892789421

SN - 6293603618

SN - 9783540310396

SP - 273

EP - 288

BT - Tumors of the Chest: Biology, Diagnosis and Management

PB - Springer Berlin Heidelberg

ER -